Hanusch Krankenhaus Der Wiener Gebietskrankenkasse
- Address
- lock Available on a paid plan
Neoplasms – Chronic Lymphocytic Leukemia
The 3rd Medical Department for Hematology and Oncology at Hanusch Krankenhaus Der Wiener Gebietskrankenkasse focuses on innovative treatments for treatment‑naive chronic lymphocytic leukemia. Ongoing research tests targeted agents such as ibrutinib and venetoclax, often combined with obinutuzumab, to improve patient outcomes.
- Efficacy comparison of continuous versus fixed‑duration regimens
- Assessment of progression‑free survival as a primary endpoint
- Exploration of combination therapies involving venetoclax, obinutuzumab, and ibrutinib
With two active studies and a team of 21 investigators, the site in Vienna is contributing to the European landscape of neoplasm research, aiming to establish safer and more effective first‑line options for patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 7 therapeutic areas and 15 of 114 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 104 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 20 by active trials.
- 1Celgene Corp.4active
lock +19 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Celgene Corp.6trials
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 152 other sites in Austria
Therapeutic Area Benchmark — Austria
Select a therapeutic area to compare against other sites in Austria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Austria
Market Share
Country: Austria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hanusch Krankenhaus Der Wiener Gebietskrankenkasse
lock Showing 1 of 54 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A multi-center, open-label, single-arm study to evaluate the efficacy and safety of oral rilzabrutinib in adults with immune thrombocytopenia (ITP) who failed first-line treatment | Sanofi-Aventis Recherche & Developpement | Phase III | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 114 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 13 | Unknown | 2014-12-18 | 2025-11-03 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.